CorMedix (CRMD) Receivables (2013 - 2025)

CorMedix has disclosed Receivables across 12 years of filings, most recently posting $171.2 million for Q4 2025.

• Receivables for Q4 2025 came in at $171.2 million, up 231.5% year-over-year; the trailing twelve-month figure through Dec 2025 was $171.2 million (up 231.5% YoY), and the FY2025 annual result was $171.2 million, up 18208.09% from the prior year.
• Receivables came in at $171.2 million for Q4 2025 at CorMedix, up from $162.6 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $171.2 million in Q4 2025 to a low of $2975.0 in Q1 2022.
• The 4-year median for Receivables is $706337.0 (2024), against an average of $36.8 million.
• Across the five-year window, Receivables jumped 1251.44% in 2021 and tumbled 93.18% in 2022, its largest moves.
• CorMedix's Receivables stood at $45368.0 in 2021, then tumbled by 93.44% to $2975.0 in 2022, then jumped by 1736168.91% to $51.7 million in 2024, then surged by 231.5% to $171.2 million in 2025.
• The last three Receivables figures came in at $171.2 million (Q4 2025), $162.6 million (Q3 2025), and $100000.0 (Q2 2025), per Business Quant data.